Skip to main content

Table 5 Basic information of extracted patients from SEER diagnosed in 2010–2015 after propensity–score matching

From: Comparison of metastasis between early-onset and late-onset gastric signet ring cell carcinoma

Variables Total Early-onset SRCC Late-onset SRCC P value
Total 464 232 232  
Sex     0.925
Male 189 (40.73%) 94 (40.52%) 95 (40.95%)  
Female 275 (59.27%) 138 (59.48%) 137 (59.05%)  
Race     0.522
White 310 (66.81%) 156 (67.24%) 154 (66.38%)  
Black 58 (25%) 32 (13.79%) 26 (11.21%)  
Other 96 (20.69%) 44 (18.97%) 52 (22.41%)  
Primary site     0.074
Cardia 54 (11.64%) 20 (8.62%) 34 (14.66%)  
Fundus 16 (6.9%) 7 (3.02%) 9 (3.88%)  
Antrum 250 (53.88%) 118 (50.86%) 132 (56.9%)  
Body 66 (14.22%) 39 (16.81%) 27 (11.64%)  
Overlappping/NOS 78 (16.81%) 48 (20.69%) 30 (12.93%)  
T stage     0.909
Tis/T1 87 (18.75%) 44 (18.96%) 43 (18.53%)  
T2 64 (13.79%) 30 (12.93%) 34 (14.66%)  
T3 149 (32.11%) 73 (31.47%) 76 (32.76%)  
T4 164 (70.69%) 85 (36.64%) 79 (34.05%)  
N stage     0.981
N0 169 (36.42%) 84 (36.21%) 85 (36.64%)  
N1 71 (15.3%) 37 (15.95%) 34 (14.66%)  
N2 90 (19.4%) 44 (18.97%) 46 (19.83%)  
N3 134 (28.88%) 67 (28.88%) 67 (28.88%)  
M stage     0.011
M0 399 (86%) 190 (80.34%) 209 (89.66%)  
M1 65 (14%) 42 (19.66%) 23 (10.34%)  
Tumor number     1
1 431 (92.89%) 215 (92.68%) 216 (93.1%)  
 > 1 33 (7.11%) 17 (7.32%) 16 (6.9%)  
Tumor size     0.926
≤ 2 cm 102 (21.98%) 50 (21.55%) 52 (22.41%)  
≤ 5 cm 174 (37.5%) 89 (38.36%) 85 (36.64%)  
 > 5 cm 188 (40.52%) 93 (40.09%) 95 (40.95%)  
Examined LNs     0.641
≤ 16 213 (45.91%) 104 (44.87%) 109 (49.06%)  
 > 16 251 (54.09%) 128 (55.13%) 123 (50.94%)  
Chemotherapy     0.849
No 182 (39.22%) 90 (38.79%) 92 (39.66%)  
Yes 282 (60.78%) 142 (61.21%) 140 (60.34%)  
\